Figure 1.

Plasma creatinine (a) and urinary albumin excretion (b) in candesartan-treated (CAN) or -untreated (c) lean and obese rats at the end of 14 weeks of treatment (n = 8 per body type/treatment). Obese had significantly increased albumin excretion and higher plasma creatinine relative to lean groups; CANtreated groups were significantly different from control by 2-way ANOVA (P < .05). ∗ indicates a significant difference (P < .05) from lean control mean and # from obese control mean by unpaired t-test.